EUVIMEDEUVIMED entdecken
Open Access

In vitro enhancement of Zika virus infection by preexisting West Nile virus antibodies in human plasma-derived immunoglobulins revealed after P2 binding site-specific enrichment

Yong He, Lilin Zhong, Hailing Yan, Maria Luisa Virata iD, Lu Deng, Ashish K Mishra, Evi Struble, Dorothy Scott, Pei Zhang iD

Microbiology Spectrum · 2024

DOI: 10.1128/spectrum.00758-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Yong He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Plasma Derivatives, Office of Plasma Protein Therapeutics CMC, Center for Biologics Evaluation and Research, U.S. Food and Drug Administr…. Hauptthemen laut MEDLINE: Zika Virus, West Nile virus, Antibodies, Viral, Zika Virus Infection. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human immunoglobulin preparations contain a diverse range of polyclonal antibodies that reflect past immune responses against pathogens encountered by the blood donor population. In this study, we examined a panel of intravenous immunoglobulins (IGIVs) manufactured over the past two decades (1998–2020) for their capacity to neutralize or enhance Zika virus (ZIKV) infection in vitro . These IGIVs were selected specifically based on their production dates in relation to the occurrences of two flavivirus outbreaks in the U.S.: the West Nile virus (WNV) outbreak in 1999 and the ZIKV outbreak in 2015. As demonstrated by enzyme-linked immunosorbent assay (ELISA) experiments, IGIVs made before the ZIKV outbreak already harbored antibodies that bind to various peptides across the envelope protein of ZIKV because of the WNV outbreak. Using phage display, the most dominant binding site was mapped precisely to the P2 peptide between residues 211 and 230 within domain II, where BF1176-56, an anti-ZIKV monoclonal antibody, also binds. When tested in permissive Vero E6 cells for ZIKV neutralization, the IGIVs, even after undergoing rigorous enrichment for P2 binding specificity, failed, as did BF1176-56. Meanwhile, BF1176-56 enhanced ZIKV infection in both FcγRII-expressing K562 cells and human peripheral blood mononuclear cells. However, for enhancement by the IGIVs to be detected in these cells, a substantial increase in their P2 binding specificity was required, thus linking the P2 site with ZIKV enhancement in vitro . Our findings warrant further study of the significance of elevated levels of anti-WNV antibodies in IGIVs, considering that various mechanisms operating in vivo may modulate ZIKV infection outcomes. IMPORTANCE We investigated the capacity of intravenous immunoglobulins manufactured previously over two decades (1998–2020) to neutralize or enhance Zika virus infection in vitro . West Nile virus antibodies in IGIVs could not neutralize Zika virus initially; however, once the IGIVs were concentrated further, they enhanced its infection. These findings lay the groundwork for exploring how preexisting WNV antibodies in IGIVs could impact Zika infection, both in vitro and in vivo . Our observations are historically significant, since we tested a panel of IGIV lots that were carefully selected based on their production dates which covered two major flavivirus outbreaks in the U.S.: the WNV outbreak in 1999 and the ZIKV outbreak in 2015. These findings will facilitate our understanding of the interplay among closely related viral pathogens, particularly from a historical perspective regarding large blood donor populations. They should remain relevant for future outbreaks of emerging flaviviruses that may potentially affect vulnerable populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Zika VirusWest Nile virusAntibodies, ViralZika Virus InfectionWest Nile FeverAntibodies, NeutralizingHumansAnimalsChlorocebus aethiopsVero CellsBinding SitesImmunoglobulins, IntravenousViral Envelope ProteinsEnzyme-Linked Immunosorbent Assay

Stichwörter der Autor:innen

Zika virusanti-WNV antibodiesantibody-dependent enhancement (ADE)cross-reactive antibodiesintravenous immunoglobulin (IGIV)

Substanzen

Antibodies, ViralAntibodies, NeutralizingImmunoglobulins, IntravenousViral Envelope Proteins

Autor:innen und Institutionen

  • Division of Plasma Derivatives, Office of Plasma Protein Therapeutics CMC, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID-Profile: Maria Luisa Virata, Pei Zhang

Zitieren

APA

He, Y., Zhong, L., Yan, H., Virata, M. L., Deng, L., Mishra, A. K., Struble, E., Scott, D., & Zhang, P. (2024). In vitro enhancement of Zika virus infection by preexisting West Nile virus antibodies in human plasma-derived immunoglobulins revealed after P2 binding site-specific enrichment. Microbiology Spectrum. https://doi.org/10.1128/spectrum.00758-24

Vancouver

He Y, Zhong L, Yan H, Virata ML, Deng L, Mishra AK, et al. In vitro enhancement of Zika virus infection by preexisting West Nile virus antibodies in human plasma-derived immunoglobulins revealed after P2 binding site-specific enrichment. Microbiology Spectrum. 2024. doi:10.1128/spectrum.00758-24

BibTeX
@article{He2024,
  author = {He, Yong and Zhong, Lilin and Yan, Hailing and Virata, Maria Luisa and Deng, Lu and Mishra, Ashish K and Struble, Evi and Scott, Dorothy and Zhang, Pei},
  title = {In vitro enhancement of Zika virus infection by preexisting West Nile virus antibodies in human plasma-derived immunoglobulins revealed after P2 binding site-specific enrichment},
  journal = {Microbiology Spectrum},
  year = {2024},
  doi = {10.1128/spectrum.00758-24}
}
Kostenlos starten →